Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jul 30, 2023
TickeronGET DAILY SIGNALS
Breaking Boundaries: Trader Robot Achieves +strong performance with $NVAX

Breaking Boundaries: Trader Robot Achieves +strong performance with $NVAX

In the ever-evolving world of finance, the integration of artificial intelligence has led to the development of sophisticated AI trading bots that promise to revolutionize the way we approach investing. One such bot, accessible through the "Swing trader: Volatility Balanced Strategy (TA)," has made headlines for its remarkable performance in the previous week, generating a substantial gain of +3.70% while actively trading NVAX (Novavax Inc.). In this article, we'll delve into the earning results and analyze the factors contributing to the impressive performance of this AI trading bot.

NVAX's Uptrend Signals Positive Outlook:

On July 10, 2023, NVAX stock price experienced a significant breakthrough as it crossed above its 50-day moving average. This technical indicator is widely regarded as a crucial sign of a change in trend direction, signaling a shift from a downward trend to an upward trend. In the past, on 31 out of 34 similar occasions, such a trend reversal has resulted in further increases in the stock price within the subsequent month. Based on historical data, the odds of NVAX continuing its upward trajectory are estimated to be as high as 90%.

Earnings Report and Market Capitalization:

Examining the most recent earnings report for NVAX, which was released on May 09, we find that the company posted earnings per share (EPS) of -341 cents. Surpassing the analyst estimates by one cent, the company's performance indicates a slightly better financial position than anticipated. With 4.88 million shares outstanding, the current market capitalization of Novavax Inc. stands at an impressive 677.49 million USD.

Understanding the Bot's Strategy:

The Swing trader: Volatility Balanced Strategy (TA) AI trading bot employs a unique strategy to navigate the stock market effectively. By leveraging historical price data and applying sophisticated algorithms, the bot identifies stocks with strong potential for an upward movement. The recent performance of NVAX is a testament to the bot's ability to capitalize on favorable market conditions and execute profitable trades.

Analyzing the Bot's Performance with NVAX:

The remarkable +strong performance achieved by the Swing trader: Volatility Balanced Strategy (TA) bot while trading NVAX over the previous week raises curiosity about its overall performance. To fully understand the bot's capabilities, it is essential to analyze its performance over a more extended period, considering multiple market conditions and different asset classes.

Summary:

The integration of AI into the financial world has opened up new possibilities for investors seeking to capitalize on market opportunities. The Swing trader: Volatility Balanced Strategy (TA) bot's impressive gain of +3.70% while trading NVAX demonstrates the potential of AI-powered trading systems. With NVAX displaying positive signals in its stock price movement and the earnings report exceeding expectations, the bot's performance has been bolstered by a favorable market environment. As AI continues to advance, these trading bots will likely play an increasingly prominent role in reshaping the landscape of modern finance.

Related Ticker: NVAX

Contributor

Dem Sem's AvatarDem Sem|Expert

NVAX in +4.49% Uptrend, rising for three consecutive days on October 29, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where NVAX advanced for three days, in 193 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 58 cases where NVAX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

Bearish Trend Analysis

The 10-day RSI Indicator for NVAX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 19 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In 72 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on October 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 41 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

NVAX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on October 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

NVAX broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NVAX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.243) is normal, around the industry mean (3.104). P/E Ratio (-6.229) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (3.759) is also within normal values, averaging (439.647).

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.19B. The market cap for tickers in the group ranges from 58 to 140.2B. VRTX holds the highest valuation in this group at 140.2B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -17%. INO experienced the highest price growth at 117%, while ABOS experienced the biggest fall at -89%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 28%. For the same stocks of the Industry, the average monthly volume growth was 53% and the average quarterly volume growth was -18%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 66
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
View a ticker or compare two or three
NVAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which engages in development of novel recombinant vaccines

Industry Biotechnology

Industry
Biotechnology
Address
21 Firstfield Road
Phone
+1 240 268-2000
Employees
749
Web
https://www.novavax.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Analysts expect Q1 2026 revenue of approximately $8.5 billion, a roughly 5% increase from $8.1 billion in Q1 2025. Consensus adjusted earnings per share (EPS) forecast stands at $4.74, reflecting a potential decline from prior-year levels amid pricing pressures.
Analysts expect Q1 2026 adjusted EPS of around $1.61, down from prior year levels due to softer commodity prices. Consensus revenue forecast stands at approximately $14.5 billion, reflecting a year-over-year decline.